Amoy Diagnostics Co Ltd (300685) - Total Liabilities
Based on the latest financial reports, Amoy Diagnostics Co Ltd (300685) has total liabilities worth CN¥272.62 Million CNY (≈ $39.89 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Amoy Diagnostics Co Ltd cash conversion from operations to assess how effectively this company generates cash.
Amoy Diagnostics Co Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Amoy Diagnostics Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Amoy Diagnostics Co Ltd (300685) asset resilience to evaluate the company's liquid asset resilience ratio.
Amoy Diagnostics Co Ltd Competitors by Total Liabilities
The table below lists competitors of Amoy Diagnostics Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alexanders Inc
NYSE:ALX
|
USA | $1.17 Billion |
|
Motic Xiamen Electric Group Co Ltd
SHE:300341
|
China | CN¥684.85 Million |
|
Gibraltar Industries Inc
NASDAQ:ROCK
|
USA | $484.12 Million |
|
MasterBrand Inc.
NYSE:MBC
|
USA | $1.76 Billion |
|
United Corporations Limited
TO:UNC
|
Canada | CA$122.62 Million |
|
Liaoning Oxiranchem Inc
SHE:300082
|
China | CN¥2.60 Billion |
|
Colorlight Cloud Tech Ltd. A
SHE:301391
|
China | CN¥478.54 Million |
|
Megaport Ltd
AU:MP1
|
Australia | AU$81.52 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Amoy Diagnostics Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Amoy Diagnostics Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amoy Diagnostics Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amoy Diagnostics Co Ltd (2012–2024)
The table below shows the annual total liabilities of Amoy Diagnostics Co Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥221.54 Million ≈ $32.42 Million |
-4.33% |
| 2023-12-31 | CN¥231.56 Million ≈ $33.88 Million |
+53.15% |
| 2022-12-31 | CN¥151.20 Million ≈ $22.12 Million |
+0.63% |
| 2021-12-31 | CN¥150.25 Million ≈ $21.99 Million |
-8.61% |
| 2020-12-31 | CN¥164.41 Million ≈ $24.06 Million |
+13.64% |
| 2019-12-31 | CN¥144.67 Million ≈ $21.17 Million |
+133.31% |
| 2018-12-31 | CN¥62.01 Million ≈ $9.07 Million |
+35.84% |
| 2017-12-31 | CN¥45.65 Million ≈ $6.68 Million |
+0.55% |
| 2016-12-31 | CN¥45.39 Million ≈ $6.64 Million |
-16.78% |
| 2015-12-31 | CN¥54.55 Million ≈ $7.98 Million |
-38.65% |
| 2014-12-31 | CN¥88.90 Million ≈ $13.01 Million |
+25.13% |
| 2013-12-31 | CN¥71.05 Million ≈ $10.40 Million |
+43.24% |
| 2012-12-31 | CN¥49.60 Million ≈ $7.26 Million |
-- |
About Amoy Diagnostics Co Ltd
Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive … Read more